Ken Griffin Inozyme Pharma, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.31 - $6.0 $9,482 - $13,200	2,200 Added 146.67%	3,700 $19,000
Q2 2024 Aug 14, 2024	SELL	$4.33 - $7.31 $433 - $731	-100 Reduced 6.25%	1,500 $6,000
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $12,833 - $23,746	-3,100 Reduced 65.96%	1,600 $12,000
Q4 2023 Feb 14, 2024	SELL	$2.71 - $4.5 $56,910 - $94,500	-21,000 Reduced 81.71%	4,700 $20,000
Q3 2023 Nov 14, 2023	BUY	$4.09 - $7.0 $92,843 - $158,900	22,700 Added 756.67%	25,700 $107,000
Q2 2023 Aug 14, 2023	SELL	$4.93 - $6.74 $16,268 - $22,242	-3,300 Reduced 52.38%	3,000 $16,000
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $8,190 - $36,099	6,300 New	6,300 $36,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $113M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.